Breathe Biologics Newsroom

Breathe Biologics, Inc. has named Ed Johnson as Chief Executive Officer.

Mr. Johnson is a seasoned biotech executive and company builder with a track record of leading organizations at the intersection of science, regulation, and commercialization. He has served in multiple C-suite roles—including Chief Executive Officer, Chief Operating Officer, and Chief Marketing Officer—guiding companies from early development through global market engagement.

In 2020, Mr. Johnson founded and led iOneBioUSA Molecular COVID-19 Technologies, where he worked directly with FDA research and regulatory frameworks while coordinating multinational collaborations with medical laboratories, hospitals, and researchers across North America, Europe, the Middle East, Africa, and Asia. His leadership focused on speed, scientific rigor, and scalable execution during a period of unprecedented global demand.

Previously, Mr. Johnson held leadership roles at Bristol Myers Squibb, contributing to the launch of five branded pharmaceutical products across multiple therapeutic areas. Over the past decade, he has advised numerous life sciences, medical device, and pharmaceutical companies on commercialization strategy, corporate development, and investor positioning.

Most recently, he served as an independent director of a publicly traded SPAC, helping complete the successful acquisition of a next-generation medical device company—demonstrating his ability to drive value creation in both private and public market environments.